Reaction Biology Corporation, a leading contract research organization providing early-stage drug discovery services, announced that it has launched a new division to provide ion-channel discovery services.
Vertex Pharmaceuticals selected two next-generation cystic fibrosis drugs to advance into late-stage testing of triple-combination therapies that could eventually treat up to 90 percent of patients.
Ferring Pharmaceuticals Inc. announced that the U.S. FDA approved Zomacton (somatropin) for Injection 5 mg and 10 mg recombinant human growth hormone (GH) indicated for replacement of GH in adults with GH deficiency.
The escalating threat of a potential nuclear war between North Korea and the United States has led the Department of Defense to join hands with a clutch of companies in developing more effective medical treatments for acute radiation syndrome.
Following a failed Phase III vaccine for stem cell transplant recipients, San Diego-based Vical Incorporated is slashing 54 percent of its employees and focusing the company’s remaining resources on two mid-stage candidates.
Dr. Brenda Fitzgerald resigned her post as director of the U.S. Centers for Disease Control and Prevention over financial conflicts of interest, the U.S. Department of Health and Human Services (HHS) said.
Bothell, Washington-based Seattle Genetics announced it is buying Seattle-based Cascadian Therapeutics for about $614 million.
The Inception Companies announce that Shaun Urban, former Managing Partner of Ogilvy CommonHealth, joined the organization as President.
Bellicum Pharmaceuticals Inc. said the FDA placed a clinical hold on U.S. trials of the company’s experimental cancer drug after three cases of brain disease linked to head trauma.
A federal judge sentenced Aegerion for improperly marketing a cholesterol drug and ordered that some of the $40.1 million it agreed to pay to resolve a U.S. investigation go to the victims.
Cancer patients’ survival prospects are improving – even for some of the deadliest types such as lung cancer – but there are huge disparities between countries, particularly for children, according to a published study.
Investors for months have fretted over a potential Amazon entry into healthcare delivery, particularly selling prescription drugs.
Rare disease giant Shire plc purchased a preclinical autoimmune drug candidate being developed by AB Biosciences.
Palo Alto, Calif.-based BridgeBio Pharma is launching a new spinout to develop a recently abandoned Novartis cancer treatment now in its possession.
The U.S. Food and Drug Administration is asking manufacturers of a common opioid medicine to change the way the drug is packaged, as part of efforts to deter its abuse amid an opioid epidemic in the United States.
Pfizer released an update of the company’s pipeline, including eight different discontinued projects in the field of neuroscience.
Eisai Inc. and Boston University School of Medicine have formed a research collaboration to study the effects of Alzheimer’s disease-associated genetic variants on the behavior of brain cells, called microglia.
Amazon.com Inc., Berkshire Hathaway and JPMorgan Chase & Co. will form a healthcare company aimed at cutting costs for their U.S. employees, they said on Tuesday, sending shares in the broad healthcare sector sharply lower.
Corbus Pharmaceuticals Holdings Inc said the U.S. Food and Drug Administration will evaluate its experimental cystic fibrosis drug without requiring proof the product improves lung function.
An experimental Roche drug designed to improve social interaction in people with autism scored the U.S. Food and Drug Administration’s Breakthrough Therapy Designation.
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.
August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!
